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The degradation of type IX collagen, a minor collagen in cartilage, was examined by treatment with three different ypes 
of matrix metalloproteinases (MMPs) purified from the culture medium of rheumatoid synovial cells. Neither MMP-1 
(collagenase) nor MMP-2 (so-called ‘gelatinase’) could digest type IX collagen, but MMP-3 (stromelysin) readily de- 
graded it into smaller fragments. This suggests that MMP-3 may be responsible for the pathological degradation and/or 
normal turnover of type IX collagen. 
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1. INTRODUCTION 
Type IX collagen is a recently characterized 
minor collagen in cartilage. Biochemical and 
molecular biological studies [l-4] have demon- 
strated that it is a heterotrimer of three disulfide- 
bonded polypeptide chains (cul, a2, a3) each con- 
taining three triple-helical domains (COLl-3), in- 
terspersed with noncollagenous domains (NCl-4). 
One of the unique properties of the molecule is the 
presence of chondroitin and dermatan sulfate- 
hybrid glycosaminoglycan chains covalently at- 
tached to the cuZ(IX) chain [5,6]. This collagen is 
co-distributed with type II collagen throughout the 
extracellular matrix of cartilage [7]. Electron- 
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Note: collagenase (EC 3.4.24.7), ‘gelatinase’ and stromelysin 
are referred to here as MMP-1, MMP-2 and MMP-3, respec- 
tively, for systematic distinction of the three matrix metallopro- 
teinases found in the same culture medium [14] 
microscopic studies of cartilage fibrils by Vaughan 
et al. [8] showed that the individual type IX 
molecules align along the type II fibril projecting 
COL3 arm and the NHZ-terminal globular (NC4) 
domain out of the fibril with a d-periodic distribu- 
tion. It is suggested that the NC4 domain with 
pl = 9.7, located away from the fibril, may 
facilitate interaction with the polyanionic pro- 
teoglycans in cartilage [9]. Moreover, biochemical 
studies demonstrated that type IX and II collagens 
are covalently attached through trivalent hydrox- 
ypyridinium cross-links [lo] formed between one 
of the chains of type IX collagen at the central 
triple helical (COL2) domain and two of the cul(I1) 
chains at either the NHZ-telopeptide [11,12] or the 
COOH-telopeptide [ 1 l] region. These data suggest 
that type IX collagen plays an important role in 
maintaining the structural integrity of cartilage.. 
Recently, the ability of human neutrophil elastase 
to digest type IX collagen was reported by Gadher 
et al. [13], but at present no information is 
available regarding the connective tissue pro- 
teinases which may be responsible for the degrada- 
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tion and/or normal turnover of this collagen in 
vivo. We report here that type IX collagen is 
degraded by matrix metalloproteinase 3 (MMP-3) 
purified from the culture medium of rheumatoid 
synovial cells [14], but is resistant o MMP-1 and 
MMP-2. 
2. MATERIALS AND METHODS 
Type IX collagen was isolated from 13-day-old chick embryo 
vitreous body by some modification of the purification methods 
reported previously [15]. The purified collagen showed im- 
munological cross-reactivity with and similar biochemical pro- 
perties to the type IX collagen derived from sternal cartilage 
except for the longer glycosaminoglycan chains attached to the 
(~2(1X) chain and lower h4, of the (Al chain (Yada, T. and 
Kimata, K., in preparation). The substrate was dissolved in 
50 mM Tris-HCl (pH 7.4)/0.15 M NaCl/lO mM CaClz/O.OWo 
Brij 35/0.02% NaNr and reacted with MMP-1, -2 or -3. 
An active form of MMP-3 (Mr 45000) was purified to 
homogeneity from the medium of rheumatoid synovial cells 
treated with rabbit macrophage-conditioned medium as in [14]. 
MMP-1 and MMP-2 were partially purified from the samples 
obtained during the MMP-3 purification steps by removal of 
contaminating metalloproteinases using Affi-Gel-gelatin and 
anti-(MMP-3) IgG-Sepharose columns for the purification of 
MMP-1, and anti-(MMP-1) and anti-(MMP-3) IgG-Sepharose 
columns for the purification of pro-MMP-2. One unit of 
MMP-1 or MMP-2 activity is defined as that digesting 1 yg col- 
lagen or 1 /cg gelatin per min at 37°C as described by Cawston 
and Barrett 1161 and Harris and Kraned [17], respectively. One 
unit of MMP-3 produces 1 ,ug reduced, carboxymethylated 
transferrin fragments oluble in 3.3% (w/v) trichloroacetic acid 
in 1 min at 37°C [14]. 
Type IX collagen (-15 fig) with or without glycosamino- 
glycan chains was incubated with MMP-3 (1 unit, 200 ng), 
MMP-2 (1 unit) or MMP-1 (1 unit) at 35’C for 6-26 h. After 
terminating the reactions with 20 mM EDTA the reaction pro- 
ducts were analyzed by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) under nonreducing and reducing conditions and 
the gels were stained with Coomassie brilliant blue. Type IX 
collagen free of glycosaminoglycans was prepared by incuba- 
tion with chondroitinase ABC (0.1 U/ml; Seikagaku Kogyo, 
Tokyo) for 12 h at 25°C. 
3. RESULTS AND DISCUSSION 
When chondroitinase ABC-treated type IX col- 
lagen was analyzed by SDS-PAGE (5% total 
acrylamide) without reduction, one major protein 
band of AYr 280000 was identified (fig.lA). Two 
minor protein bands of Mr 70000 were derived 
from the chondroitinase ABC preparation. The 
protein was susceptible to bacterial collagenase. 
Incubation of this material with MMPs and subse- 
quent analysis of the products by SDS-PAGE 
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showed that only MMP-3 degraded type IX col- 
lagen, initially into an intermediate fragment of M, 
260000 and then into a smaller fragment of M, 
230000 (fig. 1A). The latter fragment of M, 230000 
was resistant to subsequent treatment with 
MMP-2, indicating that it largely retains the triple- 
helical structure (not shown). Lower-M, fragments 
corresponding to A4, 170000, 49000 and 24000 
were also identified when larger amounts of the 
substrate (-20pg) were reacted with MMP-3 and 
analysed by SDS-PAGE with 6% acrylamide 
(fig.2). Type IX collagen was resistant o MMP-2 
and MMP-1 (fig. 1A). Similar specific degradation 
of type IX collagen by MMP-3 was also observed 
with biosynthetically radiolabeled type IX collagen 
from chick sternal cartilage (not shown). The slight 
decrease in density of the type IX collagen band 
after treatment with MMP-2 may be due to partial 
denaturation of the collagen molecule during 
preparation and/or incubation with chon- 
droitinase ABC, since MMP-2 did not cause any 
further degradation of the collagen or emergence 
of its degradation fragments even after prolonged 
incubation (fig.lA). Without chondroitinase ABC 
treatment neither type IX collagen nor its degrada- 
tion products by MMP-3 entered the stacking gel 
(3% total acrylamide). This suggests that the ma- 
jor proteolytic fragments, as well as the original 
type IX collagen, retain long glycosaminoglycan 
side chains. 
Under reducing conditions (ul(IX) and a3(IX) 
chains of intact type IX collagen were observed, 
but the a2(IX) chain was not visualized since it 
migrates diffusely at a position above the al(IX) 
chain due to the heterogeneity in size of the 
glycosaminoglycan chains covalently attached to 
this chain [5] (fig.lB). When type IX collagen was 
treated with chondroitinase ABC and elec- 
trophoresed under reducing conditions, cy chains 
wer not readily identified, since several protein 
bands derived from the chondroitinase ABC 
preparation migrated near the LY chains. Therefore, 
analyses of the reaction products of glycosamino- 
glycan-free type IX collagen under reducing condi- 
tions were not carried out. As shown in fig.lB, it 
was clear that both the al(IX) chain of Mr 61000 
and the a3(IX) chain of M, 68000 were digested by 
MMP-3 to a major fragment of Mr 47000. 
However, the LY chain from which it was derived 
was not determined. No degradation of either 
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Fig.1. SDS-PAGE of the reaction products of type IX collagen generated by incubation with MMPs. (A) Type IX collagen free of 
glycosaminoglycan chains was incubated with MMP-l-3 at 35°C for O-26 h and samples were analysed by SDS-PAGE (5% total 
acrylamide) without reduction. (B) Samples of type IX collagen with glycosaminoglycan chains reacted in the same way were run on 
a gel (7% total acrylamide) with reduction. o and B chains of type I collagen and M, values (x 10e3) of globular standard proteins 
are indica::? to the right. Approximate Mr values of type IX collagen and its degradation products were calculated by comparison 
with the mobility of collagen standards. 
Time(h) 0 10 28 
pm 
a(I) 
This study is the first to demonstrate the 
degradation of type IX collagen by a metallopro- 
teinase secreted from connective tissue cells, i.e. by 
MMP-3. Although at present the sites of cleavage 
by MMP-3 of the collagen remain unelucidated, it 
seems likely that noncollagenous domains are 
susceptible to MMP-3 since MMP-3 can remove N- 
propeptides from type I procollagen, but does not 
digest he helical region of type I collagen [ 141. The 
initial slight decrease in M, is derived from the 
degradation at either the amino-terminal or 
carboxy-terminal non-helical region. The fragment 
of A4, 230000 may be generated by proteolytic 
cleavage at either the NC3 or NC2 domain. The 
removal of either the COL3 or COOH-terminal 
CO1 domain from type IX collagen results in a 
fragment of similar size of which three cy chains are 
retained to be linked by disulfide bonds. Cysteinyl 
residues involved in interchain disulfide bonds are 
located in NC1 and NC3 domains [2]. Smaller 
fragments generated after longer incubation are 
probably due to the degradation of disulfide- 
bonded regions (fig.2). 
Fig.2. SDS-PAGE of the reaction products of type IX collagen 
free of glycosaminoglycans generated by incubation with 
MMP-3. Substrate (-2Opg) was incubated with MMP-3 at 
35°C for O-28 h and samples were subjected to SDS-PAGE 
(6% total acrylamide) without reduction. Positions where cy and 
fi chains of type I collagen migrate are indicated. MMP-3 is not only synthesized and secreted by 
chain by MMP-1 and MMP-2 confirms the obser- 
vation that type IX collagen is not susceptible to 
these enzymes as shown in fig.lA. 
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cultured rheumatoid synovial cells [14] but is also 
produced by the synovial lining cells of rheumatoid 
synovium (Okada, Y. et al., submitted). MMP-3 
digests, in addition to the action on type IX col- 
lagen reported here, cartilage proteoglycans, 
fibronectin, type IV collagen, laminin and removes 
N-propeptide of type I procollagen at neutral pH 
[14]. It has also been reported that MMP3 is 
essential for full activation of procollagenase 
[l&19]. More recently, the proteoglycan- 
degrading neutral metalloproteinase isolated from 
human articular cartilage has been identified as 
MMP-3 (stromelysin) [20]. Thus, the elevated 
proteoglycan-degrading activity found in osteoar- 
thritic cartilage [21] may be largely due to the in- 
creased production of MMP-3. These observations 
suggest that MMP-3 may play an important role in 
the destruction of articular cartilage under various 
pathological conditions such as rheumatoid ar- 
thritis and osteoarthritis deformans by degrading 
both proteoglycans and type IX collagen. 
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